2005
DOI: 10.1016/j.lungcan.2005.01.007
|View full text |Cite
|
Sign up to set email alerts
|

Clinical significance of biological differences between cavitated and solid form of squamous cell lung cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
11
0
1

Year Published

2008
2008
2021
2021

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 23 publications
(14 citation statements)
references
References 24 publications
2
11
0
1
Order By: Relevance
“…The process of cavitation in lung tumors has been associated with a poor prognosis,30 and more than 80% of cavity-forming pulmonary tumors associated with epidermal growth factor receptor overexpression exhibit rapid growth 31. Non-small cell carcinoma, especially squamous cell carcinoma, is the most common histologic type of cavity forming tumor, whereas small cell carcinoma has never been reported to cavitate 32. Rarely, cavitation or multiloculated cystic changes have been reported in lung adenocarcinoma 33.…”
Section: Cavitary Pulmonary Lesionsmentioning
confidence: 99%
“…The process of cavitation in lung tumors has been associated with a poor prognosis,30 and more than 80% of cavity-forming pulmonary tumors associated with epidermal growth factor receptor overexpression exhibit rapid growth 31. Non-small cell carcinoma, especially squamous cell carcinoma, is the most common histologic type of cavity forming tumor, whereas small cell carcinoma has never been reported to cavitate 32. Rarely, cavitation or multiloculated cystic changes have been reported in lung adenocarcinoma 33.…”
Section: Cavitary Pulmonary Lesionsmentioning
confidence: 99%
“…This suggests that RECIST 1.1 is best for evaluating patients with baseline cavitation, while mRECIST may be a more accurate method to predict PFS in patients who develop post‐therapeutic cavitation. Cavitation at baseline most often represents a rapidly expanding tumor that outgrows its blood supply and develops central necrosis, but does not represent tumor response to treatment compared with post‐therapeutic cavitation, which signifies a treatment response 17. Recent studies have generally recommended that mRECIST should be used in lung cancer with cavitation, but only applies to cases that have developed cavitation after treatment with anti‐angiogenic agents.…”
Section: Discussionmentioning
confidence: 99%
“…pared del tórax, situación extremadamente infrecuente (6). Las lesiones cavitadas tumorales pueden ser interpretadas como abscesos pulmonares y así retardar el diagnóstico durante el tratamiento de los mismos; se sabe además que en un 5 al 15% de los abscesos pulmonares se encuentra cáncer pulmonar subyacente que predispone a la infección (7), sin tener en cuenta los demás diagnósticos diferenciales como la tuberculosis pulmonar y las infecciones por Nocardia y Actinomicetos.…”
Section: Aunclassified